About this trial
This is a single-arm study aimed at evaluating the safety of TILs therapy for multiple primary early-stage NSCLC
Eligibility criteria
Qualifiers
Age 18-75 years, male or female;
Imaging findings showing multiple pulmonary nodules persisting after one year of follow-up, clinically diagnosed as multiple lung cancers by two associate senior or higher-level radiologists, two associate senior or higher-level thoracic surgeons, and one associate senior or higher-level oncologist, with patients refusing continued observation;
Patients with a history of surgical resection and pathological diagnosis of NSCLC, who subsequently show disease progression on imaging (progression of primary lesion or new nodules) during follow-up or after targeted therapy, diagnosed as lung cancer by a multidisciplinary expert team, and who refuse surgery or other treatments;
Ability to obtain a tumor sample of approximately 1-1.5 cm³ via surgery, biopsy, or bronchoscopy for preparation of autologous tumor-infiltrating lymphocytes;
Disqualifiers
Patients with pathological diagnosis of small cell lung cancer components;
Suspicious lesions appearing and follow-up duration less than six months, or remission after anti-inflammatory treatment;
Previous history of allogeneic organ transplantation or cytoreductive therapy including lymph node clearance;
Patients currently undergoing steroid therapy;
Trial design
Treatments tested in this trial
- TILs injection